Novel Lentivector Systems for In Vivo CAR & TCR Delivery for Liquid & Solid Tumor Control
11:30 am - Thursday 30th July 2026
- Developing lentivector systems using novel viral pseudotypes for improved in vivo gene delivery and possibly enabling patient redosing
- Demonstrating in vivo efficacy of CD19 CAR delivery in liquid tumor models using a novel pseudotype
- Applying this novel lentivector system to the delivery of TCRs in melanoma models, expanding therapeutic reach into solid tumor indications
